Clinical trial
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central…
NCT00335140 · Eastern Cooperative Oncology Group, Other · Terminated
Key facts
| NCT number | NCT00335140 |
|---|---|
| Title | Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma |
| Official title | Phase II Study of Rituximab Given in Conjunction With Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | Rituximab, Cytarabine, Dexamethasone, Leucovorin, Methotrexate, Procarbazine, Vincristine |
| Enrollment | 26 |
| Start date | Aug 23, 2007 |
| Primary completion | Jul 1, 2015 |
| Completion | Jul 1, 2015 |
| First posted | Jun 8, 2006 |
| Last update posted | Jul 3, 2023 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: